학술논문
How Did the Updated 2019 European Society of Cardiology/European Atherosclerosis Society Risk Categorization for Patients with Diabetes Affect the Risk Perception and Lipid Goals? A Simulated Analysis of Real-life Data from EPHESUS Study.
Document Type
Article
Author
Başaran, Özcan; Doğan, Volkan; Mert, Kadir Uğur; Özlek, Bülent; Özlek, Eda; Çelik, Oğuzhan; Çil, Cem; Özdemir, İbrahim Halil; Rencüzoğulları, İbrahim; Karadeniz, Fatma Özpamuk; Tekinalp, Mehmet; Aşkın, Lütfü; Demirelli, Selami; Gencer, Erkan; Bekar, Lütfü; Aktaş, Müjdat; Resulzade, Mübariz Murat; Kalçık, Macit; Aksan, Gökhan; Çinier, Göksel
Source
Subject
*RISK perception
*LDL cholesterol
*PEOPLE with diabetes
*RISK society
*ATHEROSCLEROSIS
*
*
*
*
Language
ISSN
2149-2263
Abstract
Background: The recent 2019 European Society of Cardiology/European Atherosclerosis Society practice guidelines introduced a new risk categorization for patients with diabetes. We aimed to compare the implications of the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines with regard to the lipid-lowering treatment use, low-density lipoprotein cholesterol goal attainment rates, and the estimated proportion of patients who would be at goal in an ideal setting. Methods: Patients with diabetes were classified into 4 risk categories according to 2019 European Society of Cardiology/European Atherosclerosis Society dyslipidemia guidelines from the database of EPHESUS (cross-sectional, observational, countrywide registry of cardiology outpatient clinics) study. The use of lipid-lowering treatment and low-density lipoprotein cholesterol goal attainment rates were then compared according to previous and new guidelines. Results: This analysis included a total of 873 diabetic adults. Half of the study population (53.8%) were on lipid-lowering treatment and almost one-fifth (19.1%) were on highintensity statins. While low-density lipoprotein cholesterol goal was achieved in 19.5% and 7.5% of patients, 87.4% and 69.6% would be on target if their lipid-lowering treatment was intensified according to 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society lipid guidelines, respectively. The new target <55 mg/dL could only be achieved in 2.2% and 8.1% of very high-risk primary prevention and secondary prevention patients, respectively. Conclusion: The control of dyslipidemia was extremely poor among patients with diabetes. The use of lipid-lowering treatment was not at the desired level, and high-intensity lipid-lowering treatment use was even lower. Our simulation model showed that the highdose statin plus ezetimibe therapy would improve goal attainment; however, it would not be possible to get goals with this treatment in more than one-third of the patients. [ABSTRACT FROM AUTHOR]